Abstract：
Helicobacter pylori (H. pylori), classified as a Group 1 carcinogen by the International Agency for Research on Cancer (IARC), is linked to gastric cancer. The progression from atrophy to metaplasia, dysplasia, and carcinoma constitutes the pathway for intestinal-type gastric carcinoma development. H. pylori infection significantly increases gastric cancer risk, particularly in individuals with atrophic gastritis. Virulence factors like CagA and VacA disrupt host signaling pathways, contributing to chronic inflammation and carcinogenesis. Pro-inflammatory cytokines and dysregulated tumor suppressor genes further fuel this process. Eradicating H. pylori reduces gastric cancer incidence, especially in patients with atrophic gastritis and/or intestinal metaplasia. However, it may not prevent cancer in those with advanced pre-neoplastic lesions. Early detection and management of H. pylori infection are crucial in mitigating gastric cancer risk, offering significant benefits.
摘要：
幽门螺杆菌(H.pylori),被国际癌症研究机构（IARC）列为第1类致癌物，与胃癌有关.从萎缩到化生的进展，发育不良,癌构成肠型胃癌发展的途径。幽门螺杆菌感染显著增加胃癌风险，特别是在患有萎缩性胃炎的个体中。毒力因子如CagA和VacA破坏宿主信号通路，导致慢性炎症和癌变。促炎细胞因子和失调的肿瘤抑制基因进一步推动了这一过程。根除幽门螺杆菌可降低胃癌发病率,尤其是萎缩性胃炎和/或肠上皮化生患者。然而,它可能无法预防晚期肿瘤前病变患者的癌症。幽门螺杆菌感染的早期检测和管理对于降低胃癌风险至关重要。提供显著的好处。
